Studies highlighting the key role of proinflammatory cytokines in RA have allowed the development of treatment targeting those molecules. IL-1band TNF inhibitors are the first step toward targeted therapies in RA. However, despite the high efficiency of these molecules, primary or acquired unresponsiveness are not uncommon, thus highlighting the necessity to elaborate alternate therapeutic means.